Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-Negative Breast Cancer Meets Primary Overall Response Rate Endpoint
-- The EVER-132-001 trial met its primary endpoint with an objective response rate of 38.8% -- FOSTER CITY, Calif., &...







